TOR1A and cranioectodermal dysplasia: As there exists multiple pathogenic gluten epitopes11–14, and as the majority of HLA-DQ2.5+ CeD patients have T cells being responsive to multiple gluten epitopes other than the DQ2.5-glia-α1a and DQ2.5-glia-α2 epitopes11–13, blocking of only a limited number of gluten pHLA-DQ2.5 molecules would not suffice for therapy.